Join
Live feed
·
PRReleasevia Quantisnow
Cadrenal Therapeutics Inc. logo

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

ByQuantisnow·Wall Street's wire, on your screen.
CVKD· Cadrenal Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CVKD (Cadrenal Therapeutics Inc.) and more on Quantisnow.